Johnson & Johnson (JNJ) PT Raised to $161.00
Johnson & Johnson (NYSE:JNJ) had its price objective raised by stock analysts at BMO Capital Markets to $161.00 in a research note issued to investors on Tuesday. The firm presently has an “outperform” rating on the stock. BMO Capital Markets’ price objective suggests a potential upside of 14.07% from the company’s current price.
JNJ has been the subject of a number of other reports. Cowen reaffirmed an “outperform” rating and set a $155.00 price objective (up from $147.00) on shares of Johnson & Johnson in a report on Wednesday, October 18th. UBS reaffirmed a “buy” rating and set a $148.00 price objective on shares of Johnson & Johnson in a report on Thursday, August 31st. Jefferies Group boosted their price target on shares of Johnson & Johnson from $157.00 to $160.00 and gave the stock a “buy” rating in a research note on Monday, October 16th. Zacks Investment Research raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Wednesday, October 4th. Finally, Credit Suisse Group set a $154.00 price target on shares of Johnson & Johnson and gave the stock an “outperform” rating in a research note on Thursday, October 19th. Four investment analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have issued a buy rating to the company’s stock. Johnson & Johnson currently has a consensus rating of “Hold” and an average target price of $145.04.
Johnson & Johnson (NYSE:JNJ) traded up $0.55 on Tuesday, hitting $141.14. 4,358,600 shares of the stock were exchanged, compared to its average volume of 5,861,946. The stock has a market cap of $384,670.00, a price-to-earnings ratio of 19.69, a P/E/G ratio of 2.86 and a beta of 0.80. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.32 and a quick ratio of 1.02. Johnson & Johnson has a 12-month low of $110.76 and a 12-month high of $144.35.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Harding Loevner LP purchased a new stake in Johnson & Johnson in the second quarter worth about $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its holdings in Johnson & Johnson by 29.9% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock worth $115,000 after purchasing an additional 200 shares during the period. Lenox Wealth Advisors Inc. grew its holdings in Johnson & Johnson by 0.6% in the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock worth $116,000 after purchasing an additional 5 shares during the period. IHT Wealth Management LLC grew its holdings in Johnson & Johnson by 46.4% in the second quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock worth $122,000 after purchasing an additional 3,467 shares during the period. Finally, Mountain Capital Investment Advisors Inc purchased a new stake in Johnson & Johnson in the second quarter worth about $124,000. Institutional investors own 65.89% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This news story was reported by American Banking News and is owned by of American Banking News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/12/12/johnson-johnson-jnj-pt-raised-to-161-00.html.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.